In 2022，multiple research milestones have occurred in the field of Alzheimer’s disease(AD). The genetic and pathological mechanisms of AD continued to be deepened and innovated. The rapeutics went through a fundamental transition from symptomatic modification therapy to targeted modification therapy，with amyloid-β targeted drugs gradually moving from clinical trials into real - world application. Encouraging findings on biomarkers and risk factors also marked the ongoing shift toward sprecise diagnosis and early prevention.